It is also known as a stable gastric pentadecapeptide primarily because it is stable in human gastric juice, can cause an anabolic healing effect in both the upper and lower GI tract, has an antiulcer effect, and produces a therapeutic effect on inflammatory bowel disease (IBD)all again surprisingly free of side effects
With clinical trials ongoing, phase 3 results arrive in 2026, guiding future treatment guidelines and potentially FDA approval
Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: a case report
The federal rule is that you cannot use the Bridge to access a drug that your Part D plan would cover for another indication
Affordable self-pay options may be available for eligible patients without insurance coverage or for those who prefer not to use insurance
Without coverage, the Medicare Plan Finder shows monthly costs for some of these drugs can exceed $1,000